MedTrace Logo

Study to Evaluate Xtressé Gummy Supplement in Men With Androgenic Alopecia

NCT07637071 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-06-10

No results posted yet for this study

Summary

The goal of this study is to determine how safe and effective it is to improve hair growth using an active gummy treatment in men with androgenic alopecia.

The main aims of this trial are:

1. To confirm using photographic analysis, changes in the quality, volume, and thickness of hair.
2. To gauge patient satisfaction with hair changes and application process.
3. Monitor and report any adverse events associated with the daily intake of Xtressé

Participants who qualify will complete 3 visits after voluntary consent has been given. Participants will be given a 90-day supply of the gummies at visits 1 and 2 to cover the 6-month study period. Photographs and scalp analysis will be performed at each visit to measure changes in hair volume, thickness, and growth.

Conditions

  • Androgenic Alopecia
  • Hair Loss/Baldness
  • Hair Thinning

Interventions

OTHER

Xtressé Hair Growth Gummies

The nutraceutical supplement is powered by proprietary X-3 BioActive Blend and contains plant based extracts and regenerative compounds not commonly found in existing hair supplements. The dosage is 2 gummies taken once per day.

Sponsors & Collaborators

  • Restore Biologics Holdings, Inc. dba Xtressé

    lead INDUSTRY

Principal Investigators

  • Melissa Y Rayner, MS · Restore Biologics Holdings, Inc. dba Xtressé

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-22
Primary Completion
2027-01-31
Completion
2027-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07637071 on ClinicalTrials.gov